No connection

Search Results

ADTX vs BDRX

ADTX
Aditxt, Inc.
BEARISH
Price
$1.82
Market Cap
$0.4M
Sector
Healthcare
AI Confidence
95%
BDRX
Biodexa Pharmaceuticals Plc
BEARISH
Price
$2.15
Market Cap
$1.8M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
ADTX
--
BDRX
--
Forward P/E
ADTX
-0.16
BDRX
--
P/B Ratio
ADTX
-0.01
BDRX
0.09
P/S Ratio
ADTX
67.96
BDRX
--
EV/EBITDA
ADTX
-0.22
BDRX
-15012.8

Profitability

Gross Margin
ADTX
0.0%
BDRX
0.0%
Operating Margin
ADTX
-419870.0%
BDRX
0.0%
Profit Margin
ADTX
0.0%
BDRX
0.0%
ROE
ADTX
--
BDRX
-61.77%
ROA
ADTX
-61.7%
BDRX
-39.04%

Growth

Revenue Growth
ADTX
-89.1%
BDRX
--
Earnings Growth
ADTX
--
BDRX
--

Financial Health

Debt/Equity
ADTX
--
BDRX
0.04
Current Ratio
ADTX
0.02
BDRX
3.63
Quick Ratio
ADTX
0.02
BDRX
3.63

Dividends

Dividend Yield
ADTX
--
BDRX
--
Payout Ratio
ADTX
0.0%
BDRX
0.0%

AI Verdict

ADTX BEARISH

ADTX exhibits severe financial distress, reflected in a Piotroski F-Score of 1/9 (indicating weak financial health) and a lack of an Altman Z-Score, which raises significant bankruptcy risk. The company is unprofitable with a negative ROA of -61.70%, a gross margin of 0.00%, and a staggering -419,870.30% operating margin. Revenue has collapsed by 89.10% YoY, and the stock has declined 100% over the past five years. Despite a low price of $1.82, the valuation metrics are nonsensical (e.g., Price/Sales of 67.96, negative P/E), suggesting extreme overvaluation or data failure. The absence of any analyst coverage and negative insider activity further confirm a lack of institutional confidence.

Strengths
Minimal market cap may offer speculative appeal for high-risk investors
Recent quarter showed a slight Q/Q EPS improvement (+6.9%)
One quarter beat earnings estimate (1/4), indicating potential for volatility in results
Risks
Piotroski F-Score of 1/9 indicates extreme financial weakness and poor operational efficiency
Negative ROA (-61.70%) and operating margin (-419,870.30%) signal severe profitability collapse
Revenue declined 89.10% YoY, with inconsistent and erratic earnings surprises (avg -96.38%)
BDRX BEARISH

The Advanced Deterministic Scorecard reveals a critically weak financial profile with a Piotroski F-Score of 2/9, indicating severe operational and financial distress. Despite a strong current and quick ratio suggesting short-term liquidity, the company is unprofitable across all margins, with deeply negative ROE and ROA. Valuation metrics are largely undefined due to lack of earnings and revenue data, while the stock has lost nearly all value over the past year. Insider sentiment is neutral-to-weak, and there is no analyst coverage or dividend support, amplifying risk.

Strengths
Strong liquidity position with current and quick ratios of 3.63, indicating ability to cover short-term liabilities.
Low debt/equity ratio of 0.04, reflecting minimal leverage risk.
Two out of three recent quarters beat earnings estimates, showing some operational predictability.
Risks
Piotroski F-Score of 2/9 indicates very weak financial health and high risk of continued deterioration.
No Altman Z-Score available, but negative ROE (-61.77%) and ROA (-39.04%) suggest high bankruptcy risk.
Profitability metrics are entirely negative: 0% gross, operating, and profit margins.

Compare Another Pair

ADTX vs BDRX: Head-to-Head Comparison

This page compares Aditxt, Inc. (ADTX) and Biodexa Pharmaceuticals Plc (BDRX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile